Back to top
more

Artivion (AORT)

(Real Time Quote from BATS)

$31.92 USD

31.92
73,683

-0.14 (-0.44%)

Updated Aug 5, 2025 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Equity Research

Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Intuitive Surgical, Inc. (ISRG) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Equity Research

Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year.

Zacks Equity Research

Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD

by Zacks Equity Research

Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.

Shaun Pruitt headshot

Time to Buy These Medical Stocks as Earnings Approach

by Shaun Pruitt

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

Zacks Equity Research

Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Artivion (AORT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 500% and 5.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 166.67% and 2.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Sight Sciences, Inc. (SGHT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Artivion (AORT) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Wall Street Analysts Think Artivion (AORT) Could Surge 79%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 79.4% upside potential for Artivion (AORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 173.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SARTORIUS (SARTF) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

SARTORIUS (SARTF) delivered earnings and revenue surprises of 7.39% and 7.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 0% and 4.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Artivion (AORT) a New Buy Stock

by Zacks Equity Research

Artivion (AORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).